Nystatin prophylaxis in immunocompromised children

Area of Science:

• Mycology
• Hematology
• Oncology
• Bone Marrow Transplantation

Background:

• Hematology/oncology/bone marrow transplantation patients are at high risk for invasive fungal infections.
• Fungal prophylaxis is crucial in immunocompromised patient populations.
• Nystatin is a commonly considered antifungal agent for prophylaxis.

Purpose of the Study:

• To evaluate the efficacy of nystatin for fungal prophylaxis in hematology/oncology/bone marrow transplantation patients.
• To determine if nystatin reduces the incidence of disseminated fungal infections in this cohort.

Main Methods:

• Review of existing literature on nystatin use for fungal prophylaxis.
• Analysis of studies comparing nystatin with placebo or no therapy.
• Assessment of nystatin's impact on fungal colonization and invasive infections.

Main Results:

• Nystatin showed little to no benefit over no therapy in preventing disseminated fungal infections.
• Nystatin significantly reduced multiple-site fungal colonization and persistent oropharyngeal cultures.
• The study did not find nystatin effective in preventing invasive fungal infections.

Conclusions:

• Nystatin provides limited benefit for fungal prophylaxis in immunocompromised patients.
• Alternative antifungal agents like ketoconazole, fluconazole, itraconazole, or amphotericin B may offer better protection.
• Further research comparing nystatin with other antifungals is warranted.